Cargando…

COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats

Through the experiences gained by accelerating new vaccines for both Ebola virus infection and COVID-19 in a public health emergency, vaccine development has benefited from a ‘multiple shots on goal’ approach to new vaccine targets. This approach embraces simultaneous development of candidates with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotez, Peter J, Gilbert, Sarah, Saville, Melanie, Privor-Dumm, Lois, Abdool-Karim, Salim, Thompson, Didi, Excler, Jean-Louis, Kim, Jerome H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254949/
https://www.ncbi.nlm.nih.gov/pubmed/37277196
http://dx.doi.org/10.1136/bmjgh-2023-011883
_version_ 1785056762333757440
author Hotez, Peter J
Gilbert, Sarah
Saville, Melanie
Privor-Dumm, Lois
Abdool-Karim, Salim
Thompson, Didi
Excler, Jean-Louis
Kim, Jerome H
author_facet Hotez, Peter J
Gilbert, Sarah
Saville, Melanie
Privor-Dumm, Lois
Abdool-Karim, Salim
Thompson, Didi
Excler, Jean-Louis
Kim, Jerome H
author_sort Hotez, Peter J
collection PubMed
description Through the experiences gained by accelerating new vaccines for both Ebola virus infection and COVID-19 in a public health emergency, vaccine development has benefited from a ‘multiple shots on goal’ approach to new vaccine targets. This approach embraces simultaneous development of candidates with differing technologies, including, when feasible, vesicular stomatitis virus or adenovirus vectors, messenger RNA (mRNA), whole inactivated virus, nanoparticle and recombinant protein technologies, which led to multiple effective COVID-19 vaccines. The challenge of COVID-19 vaccine inequity, as COVID-19 spread globally, created a situation where cutting-edge mRNA technologies were preferentially supplied by multinational pharmaceutical companies to high-income countries while low and middle-income countries (LMICs) were pushed to the back of the queue and relied more heavily on adenoviral vector, inactivated virus and recombinant protein vaccines. To prevent this from occurring in future pandemics, it is essential to expand the scale-up capacity for both traditional and new vaccine technologies at individual or simultaneous hubs in LMICs. In parallel, a process of tech transfer of new technologies to LMIC producers needs to be facilitated and funded, while building LMIC national regulatory capacity, with the aim of several reaching ‘stringent regulator’ status. Access to doses is an essential start but is not sufficient, as healthcare infrastructure for vaccination and combating dangerous antivaccine programmes both require support. Finally, there is urgency to establish an international framework through a United Nations Pandemic Treaty to promote, support and harmonise a more robust, coordinated and effective global response.
format Online
Article
Text
id pubmed-10254949
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102549492023-06-10 COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats Hotez, Peter J Gilbert, Sarah Saville, Melanie Privor-Dumm, Lois Abdool-Karim, Salim Thompson, Didi Excler, Jean-Louis Kim, Jerome H BMJ Glob Health Analysis Through the experiences gained by accelerating new vaccines for both Ebola virus infection and COVID-19 in a public health emergency, vaccine development has benefited from a ‘multiple shots on goal’ approach to new vaccine targets. This approach embraces simultaneous development of candidates with differing technologies, including, when feasible, vesicular stomatitis virus or adenovirus vectors, messenger RNA (mRNA), whole inactivated virus, nanoparticle and recombinant protein technologies, which led to multiple effective COVID-19 vaccines. The challenge of COVID-19 vaccine inequity, as COVID-19 spread globally, created a situation where cutting-edge mRNA technologies were preferentially supplied by multinational pharmaceutical companies to high-income countries while low and middle-income countries (LMICs) were pushed to the back of the queue and relied more heavily on adenoviral vector, inactivated virus and recombinant protein vaccines. To prevent this from occurring in future pandemics, it is essential to expand the scale-up capacity for both traditional and new vaccine technologies at individual or simultaneous hubs in LMICs. In parallel, a process of tech transfer of new technologies to LMIC producers needs to be facilitated and funded, while building LMIC national regulatory capacity, with the aim of several reaching ‘stringent regulator’ status. Access to doses is an essential start but is not sufficient, as healthcare infrastructure for vaccination and combating dangerous antivaccine programmes both require support. Finally, there is urgency to establish an international framework through a United Nations Pandemic Treaty to promote, support and harmonise a more robust, coordinated and effective global response. BMJ Publishing Group 2023-06-05 /pmc/articles/PMC10254949/ /pubmed/37277196 http://dx.doi.org/10.1136/bmjgh-2023-011883 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Analysis
Hotez, Peter J
Gilbert, Sarah
Saville, Melanie
Privor-Dumm, Lois
Abdool-Karim, Salim
Thompson, Didi
Excler, Jean-Louis
Kim, Jerome H
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
title COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
title_full COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
title_fullStr COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
title_full_unstemmed COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
title_short COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
title_sort covid-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
topic Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254949/
https://www.ncbi.nlm.nih.gov/pubmed/37277196
http://dx.doi.org/10.1136/bmjgh-2023-011883
work_keys_str_mv AT hotezpeterj covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats
AT gilbertsarah covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats
AT savillemelanie covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats
AT privordummlois covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats
AT abdoolkarimsalim covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats
AT thompsondidi covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats
AT exclerjeanlouis covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats
AT kimjeromeh covid19vaccinesandthepandemiclessonslearntforotherneglecteddiseasesandfuturethreats